RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9

Benzinga · 1d ago
RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.